Bina Technologies is acquired by Roche
REDWOOD CITY, Calif., Dec. 19, 2014-- Bina Technologies, Inc. (Bina, Redwood City, CA, USA) announced today that they have been acquired by Roche (SIX: RO, ROG; OTCQX: RHHBY). Bina Technologies1,2 is a privately held company that provides a big data platform for centralized management and processing of next generation sequencing (NGS) data for the academic and translational research markets. Bina will be integrated into the Roche Sequencing Unit, and will continue to focus on development of their innovative genomic analysis solution.
"Roche's acquisition of Bina is a great validation of our work and technology. It is also an indication of how informatics and data science are going to play a major role in the future of medicine," said Narges Bani Asadi, Founder and CEO of Bina. "We found great alignment between our company's vision and values, and we are very excited about the possibilities of working with Roche's global team and serving the academic and translational and clinical research markets together in the future."
Bina's proprietary Genomic Management Solution, the Bina-GMS, is expected to dramatically improve the speed and cost of genomic analyses. Bina recently announced selection of their platform by the US Department of Veterans Affairs (VA) to provide whole genome, whole exome, and SNP Chip DNA data analysis as part of the VA's Million Veteran Program (MVP), which aims to enroll 1 million veterans. The acquisition by Roche will enable Bina to further expand support to similar big-data population studies, as well as grow their offering for global enterprise and clinical research customers.
"The acquisition of Bina is a significant step for Roche to enable the promise of personalized healthcare by delivering the highest quality genomic data possible," said Dan Zabrowski, Head of Roche Sequencing. "Informatics and data management are critical to providing a seamless, end-to-end sequencing solution. Bina's products are designed to improve the efficiency and value of genomic analysis, and the company continues to develop new methodologies and algorithms that link NGS data to disease-relevant genetic markers."
The acquisition by Roche will enable Bina to accelerate product development and global commercialization of the Bina Genomic Management System as an enterprise software system supporting multiple sequencing technologies while developing a solution for Roche sequencing systems. Roche will help Bina to continue to grow their unique interdisciplinary team of bioinformatics scientists, computer scientists and software engineers.
1Bina products are for Research Use Only. Not for use in diagnostic procedures.
2Bina is backed by Sierra Ventures, Signatures Capital, Columbus Nova Technology Partners, and AME Cloud Ventures.
About Bina Technologies
Bina Technologies builds next-generation technologies for scalable and accurate processing and management of genomic information. Bina's Genomic Management Solution is an integrated, scalable, and comprehensive analysis platform that empowers clinical and translational researchers to gain insight from their genomic data sets. Bina's Genomic Management Solution dramatically decreases the complexity, time, and cost of genomic analysis, accelerating the science of personalized medicine. Learn more about Bina's product, technologies, and team at http://www.bina.com
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.